Welcome to the international HTA database

Showing [23809 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Endoscopic radiofrequency ablation for Barrett's oesophagus with low-grade dysplasia or no dysplasia. NICE interventional procedures guidance 496
2014	Health Quality Ontario (HQO)	Frequency of testing for dyslipidemia: a systematic review and budget impact analysis
2014	Blue Cross Blue Shield Association (BCBS)	CYP2D6 pharmacogenomics of tamoxifen treatment
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ocrelizumab for primary progressive multiple sclerosis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Off-label use of 5HT3 antagonists: clinical evidence and guidelines
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. NICE interventional procedures guidance 497
2014	Health Quality Ontario (HQO)	Multiple intravenous infusions phases 2a and 2b: OHTAC recommendation
2014	Blue Cross Blue Shield Association (BCBS)	Transcranial magnetic stimulation for depression
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Curelator Headache™ digital platform for adults with migraine
2014	Blue Cross Blue Shield Association (BCBS)	Fecal DNA analysis for colorectal cancer screening
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nebulized Lidocaine for patients with nasal trauma: clinical effectiveness and guidelines
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Canagliflozin/metformin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Powered microdebrider turbinoplasty for inferior turbinate hypertrophy. NICE interventional procedures guidance 498
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Building planning and infection control: hand hygiene dispensers and individual bathrooms in residential and long-term care centres]
2014	Blue Cross Blue Shield Association (BCBS)	Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction
2014	NIHR Horizon Scanning Centre (NIHR HSC)	SensiumVitals® vital signs monitoring patch
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ankle braces for the prevention of injury in sport: clinical effectiveness
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Endoscopic saphenous vein harvest for coronary artery bypass grafting. NICE interventional procedures guidance 494
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Efficacy of neglect interventions for Indigenous children, families and communities]
2014	Blue Cross Blue Shield Association (BCBS)	Gene expression analysis for prostate cancer management
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Peramivir for acute uncomplicated influenza in adults
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Velaglucerase alfa
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ketorolac for pain management: a review of the clinical evidence
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nalmefene - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Radiofrequency tissue reduction for turbinate hypertrophy. NICE interventional procedures guidance 495
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Public policies for the coverage of continuous positive airway pressure devices for the treatment of obstructive sleep apnea]
2014	Blue Cross Blue Shield Association (BCBS)	Myocardial sympathetic innervation imaging in heart failure
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ivacaftor (Kalydeco) for an additional 8 mutations in cystic fibrosis (licence extension)
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cystoscopy for the diagnosis of patients with urological issues: guidelines
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Teriflunomide for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 303
2014	National Institute for Health and Care Excellence (NICE)	Gastroelectrical stimulation for gastroparesis. NICE interventional procedures guidance 489
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Real-time magnetic resonance imaging (MRI)-guided radiation therapy]
2014	Blue Cross Blue Shield Association (BCBS)	Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine
2014	NIHR Horizon Scanning Centre (NIHR HSC)	InterVapor® System for the treatment of severe emphysema
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Imatinib (Glivec®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Teduglutide - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip. NICE technology appraisal guidance 304
2014	National Institute for Health and Care Excellence (NICE)	Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. NICE interventional procedures guidance 487
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Management of the extravasation of antineoplastic agents]
2014	Blue Cross Blue Shield Association (BCBS)	Artificial pancreas device systems
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ivermectin 1% topical cream for papulopustular rosacea
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Eltrombopag (Revolade®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interferon-free regimens for chronic hepatitis C genotype 1
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance 305
2014	National Institute for Health and Care Excellence (NICE)	Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee. NICE interventional procedures guidance 493
2014	NIHR Health Technology Assessment programme	Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds
2014	Blue Cross Blue Shield Association (BCBS)	Special report: screening asymptomatic women with dense breasts and normal mammograms for breast cancer
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Thymosin beta-4 for epidermolysis bullosa
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Lipegfilgrastim (Lonquex®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Obesity interventions delivered in primary care for patients with diabetes: a review of clinical effectiveness
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. NICE technology appraisal guidance 306
2014	National Institute for Health and Care Excellence (NICE)	Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. NICE interventional procedures guidance 482
2014	NIHR Health Technology Assessment programme	European network for Health Technology Assessment Joint Action (EUnetHTA JA): a process evaluation performed by questionnaires and documentary analysis
2014	NIHR Health Technology Assessment programme	The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials
2014	NIHR Horizon Scanning Centre (NIHR HSC)	CelluTome™ epidermal harvesting system for autologous skin grafting
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interferon-free regimens for genotype 1 chronic hepatitis C: a review of the clinical evidence and cost-effectiveness
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-21 (Fingolimod)]
2014	National Institute for Health and Care Excellence (NICE)	Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. NICE technology appraisal guidance 307
2014	National Institute for Health and Care Excellence (NICE)	Insertion of a magnetic bead band for faecal incontinence. NICE interventional procedures guidance 483
2014	NIHR Health Technology Assessment programme	Maximising the value of combining qualitative research and randomised controlled trials in health research: the QUAlitative Research in Trials (QUART) study a mixed methods study
2014	NIHR Health Technology Assessment programme	Coronary artery bypass grafting in high-RISk patients randomised to off- or on-Pump surgery: a randomised controlled trial (the CRISP trial)
2014	HAYES, Inc.	Antimicrobial central venous catheters
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (extension of approval) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. NICE technology appraisal guidance 308
2014	National Institute for Health and Care Excellence (NICE)	Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. NICE interventional procedures guidance 484
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Dinutuximab (Unituxin) for high risk neuroblastoma – maintenance therapy
2014	Health Council of the Netherlands Gezondheidsraad (GR)	ADHD: medication and society
2014	HAYES, Inc.	Combined positron emission tomography-computed tomography (PET-CT) for evaluating esophageal cancer
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Azithromycin (Zedbac®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Patient-controlled analgesia for pediatric surgical or cancer patients: clinical effectiveness
2014	National Institute for Health and Care Excellence (NICE)	Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 310
2014	National Institute for Health and Care Excellence (NICE)	Faecal microbiota transplant for recurrent Clostridium difficile infection. NICE interventional procedures guidance 485
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Blinatumomab for relapsed or refractory Philadelphia-negative B-precursor acute lymphoblastic leukaemia
2014	Health Council of the Netherlands Gezondheidsraad (GR)	Participation by young people with mental health problems
2014	HAYES, Inc.	Combined positron emission tomography-computed tomography (PET-CT) for evaluating gastric and colorectal cancers
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Aripiprazole monohydrate (Abilify Maintena®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Personal protective equipment for antibiotic resistant organisms in rehabilitation facilities: clinical evidence and guidelines
2014	NIHR Health Technology Assessment programme	Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism [ID726]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. NICE technology appraisal guidance 311
2014	National Institute for Health and Care Excellence (NICE)	Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. NICE interventional procedures guidance 478
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Lapatinib (Tyverb) for early HER2-positive breast cancer, neoadjuvant therapy in combination with trastuzumab
2014	NIHR Health Technology Assessment programme	Changing eating behaviours to treat childhood obesity in the community using Mandolean: the Community Mandolean randomised controlled trial (ComMando) - a pilot study
2014	HAYES, Inc.	Cranial orthotic devices for the treatment of positional cranial deformity
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Dolutegravir (Tivicay®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term 5HT3 antagonist use for tinnitus: clinical evidence and guidelines
2014	NIHR Health Technology Assessment programme	Aflibercept solution for injection for treating diabetic macular oedema [ID717]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sucroferric oxyhydroxide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]